Aptevo Therapeutics Inc. (APVO)

Aptevo Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	3.11	12.29	4.31
Revenue Growth (YoY)	-	-	-74.67%	185.26%	-
Cost of Revenue	-	-	17.88	18.99	17.85
Gross Profit	-	-	-14.77	-6.7	-13.54
Selling, General & Admin	10.22	11.77	13.87	14.7	13.95
Research & Development	14.38	17.11	-	-	-
Operating Expenses	24.6	28.88	13.87	14.7	13.95
Operating Income	-24.6	-28.88	-28.64	-21.4	-27.49
Other Non Operating Income (Expenses)	0.47	0.58	-1.53	-8.01	-1.33
EBT Excluding Unusual Items	-24.13	-28.3	-30.17	-29.41	-28.82
Gain (Loss) on Sale of Assets	-	9.65	-	-	-
Other Unusual Items	-	-	37.18	-	-2.1
Pretax Income	-24.13	-18.65	7.01	-29.41	-30.92
Earnings From Continuing Operations	-24.13	-18.65	7.01	-29.41	-30.92
Earnings From Discontinued Operations	-	1.24	1.01	0.95	13.17
Net Income	-24.13	-17.41	8.03	-28.46	-17.75
Net Income to Common	-24.13	-17.41	8.03	-28.46	-17.75
Shares Outstanding (Basic)	0	-	-	-	-
Shares Outstanding (Diluted)	0	-	-	-	-
EPS (Basic)	-87.38	-	-	-	-
EPS (Diluted)	-87.38	-	-	-	-
Free Cash Flow	-23.79	-11.73	-21.05	-22.39	-29.41
Free Cash Flow Per Share	-86.14	-	-	-	-
Gross Margin	-	-	-	-54.52%	-
Operating Margin	-	-	-919.75%	-174.10%	-638.06%
Profit Margin	-	-	257.77%	-231.51%	-411.93%
Free Cash Flow Margin	-	-	-676.01%	-182.17%	-682.43%
EBITDA	-24.25	-28.31	-27.74	-20.26	-26.19
EBITDA Margin	-	-	-	-164.79%	-
D&A For EBITDA	0.35	0.57	0.9	1.14	1.31
EBIT	-24.6	-28.88	-28.64	-21.4	-27.49
EBIT Margin	-	-	-	-174.10%	-

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q